Skip to main content
Clinical Trials/NCT00330265
NCT00330265
Unknown
Phase 2

A Prospective, Randomized, Controlled, Unmasked, Multiple Treatment, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of an Interactive Wound Dressing Containing Cultured Keratinocytes Versus Conventional Wound Therapy for the Treatment of Diabetic Foot Ulcers

KeraCure21 sites in 1 country300 target enrollmentJanuary 2006

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Foot Ulcer
Sponsor
KeraCure
Enrollment
300
Locations
21
Primary Endpoint
Percent of subjects achieving complete or (100%) study wound closure by week 12 after initial treatment
Last Updated
17 years ago

Overview

Brief Summary

The objective of this study is to determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.

This is a prospective, randomized, multi-center, unmasked, controlled study. All patients will receive care for the diabetic foot ulcer during the study.

Participation in the study is for 24 weeks.

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
September 2009
Last Updated
17 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
KeraCure

Eligibility Criteria

Inclusion Criteria

  • Participants included in the study must:
  • Have Type 1 or Type 2 diabetes mellitus
  • Have a diabetic foot ulcer on the bottom of the foot or heal which has been present for three (3) weeks but less than two (2) years and is sufficient size to qualify for the study
  • Be able to visit the study doctor regularly for 24 weeks

Exclusion Criteria

  • Participants may not be included if:
  • The diabetic foot ulcer is infected
  • They have poor circulation in their study foot
  • Cannot or will not wear a special boot to take pressure off the study ulcer
  • They have certain other diseases or laboratory values which are not within a specified range

Outcomes

Primary Outcomes

Percent of subjects achieving complete or (100%) study wound closure by week 12 after initial treatment

Time Frame: 12 weeks

Study Sites (21)

Loading locations...

Similar Trials